Effect of KW-6356, a novel adenosine A2A receptor antagonist/inverse agonist, on motor and non-motor symptoms in Parkinson’s disease patients as an adjunct to levodopa therapy: Results of Phase 2b study
Objective: To evaluate the efficacy and safety of KW-6356 in Parkinson’s disease (PD) patients with levodopa therapy, irrespective of the presence of wearing-off (WO). Background:…Use of apomorphine infusion pump in the elderly population : a 5 years follw up study on efficacy, safety and tolerability in a cohort bases study
Objective: Evaluate the efficacy, tolerability and safety of subcutaneous apomorphine infusion in elderly patients with advanced Parkinson's disease in a five years follow up cohort. Background: Continuous infusion by subcutaneous apomorphine pump has…Testamentary Capacity Assessment Tool (TCAT): An update report
Objective: The present study reviews all studies about TCAT and its use in clinical settings, as well as its validation in different cultures. Background: TCAT…Predictors of the change in burden and strain among caregivers of Parkinson’s disease patients
Objective: The aim of the present study was to analyze the change in burden and strain after a 2-year follow-up in a cohort of caregivers…Safety and Efficacy of unilaterally Focused Ultrasound Subthalamotomy in Early Parkinson´s Disease: The EARLY FOCUS I Study
Objective: To assess the safety and efficacy of unilateral FUS subthalamotomy in early PD patients. Background: FUS subthalamotomy is feasible and therapeutically effective in Parkinson´s…Globus pallidus as a neurosurgical target in the management of levodopa-induced dyskinesias
Objective: Parkinson's disease (PD) is a neurodegenerative disorder characterized by the development of motor symptoms, as well as some non-motor changes. Symptomatic treatment of PD…Caregiver burden and quality of life in late stage Parkinson’s disease
Objective: To describe and assess factors associated with informal caregiver quality of life (QoL) in late stage Parkinson’s disease (PD). Background: In the late stage…The effects of converting to Dysport from other botulinum toxin type A formulations for treating cervical dystonia patients
Objective: To investigate whether Dysport increases waning time compared to other botulinum toxin type A (BoNT-A) formulations for cervical dystonia (CD) therapy. Background: BoNT-A injections…Dysphagia and its relationship to medication intake in Parkinson’s disease
Objective: This study attempted to obtain a comprehensive picture of medication intake dysphagia in Parkinson’s disease (PD). Specific investigations included 1) An objective, graduated and…DystoniaBoTXNet: A Deep Learning Platform for Predictive Outcome of Botulinum Toxin Treatment in Isolated Dystonia
Objective: To develop and validate an objective measure of the botulinum toxin treatment outcome in isolated dystonia. Background: Dystonia is characterized by abnormal, often painful,…
- « Previous Page
- 1
- …
- 70
- 71
- 72
- 73
- 74
- …
- 153
- Next Page »